Document is current

Article History

Accepted: 14 May 2023

First Online: 3 June 2023

Declarations

:

: DDF and DH report no conflicts of interest.DD reports the following disclosures:Grants/research support (institutional): Arcus, CellSight Technologies, Immunocore, Merck, Regeneron Pharmaceuticals Inc., Tesaro/GSKConsultant: ACM Bio, Ascendis Pharma, Clinical Care Options (CCO), Gerson Lehrman Group (GLG), Merck, Medical Learning Group (MLG), Xilio TherapeuticsCE Speakers’ Bureau: Castle Biosciences.Stockholder: None.Intellectual Property:US Patent 63/124,231, “Compositions and Methods for Treating Cancer”, Dec 11, 2020US Patent 63/208,719, “Compositions and Methods For Determining Responsiveness to Immune Checkpoint Inhibitors (ICI), Increasing Effectiveness of ICI and Treating Cancer”, June 9, 2021.